{"id":"escitalopram-bupropion-sr","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Nausea"},{"rate":"10-20","effect":"Insomnia"},{"rate":"10-15","effect":"Headache"},{"rate":"5-15","effect":"Dry mouth"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Tremor"},{"rate":"10-15","effect":"Sexual dysfunction"},{"rate":"5-10","effect":"Sweating"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that blocks the reuptake of serotonin at the synaptic cleft, increasing serotonin availability. Bupropion SR is a norepinephrine-dopamine reuptake inhibitor (NDRI) that blocks reuptake of norepinephrine and dopamine. Together, they provide complementary monoaminergic effects to treat depression and related mood disorders.","oneSentence":"This combination increases serotonin and norepinephrine signaling in the brain through selective serotonin reuptake inhibition and dopamine/norepinephrine reuptake inhibition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:35.654Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Treatment-resistant depression"}]},"trialDetails":[{"nctId":"NCT06675851","phase":"PHASE4","title":"Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2022-12-01","conditions":"Major Depressive Disorder (MDD)","enrollment":120},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT00564278","phase":"NA","title":"Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-02","conditions":"Depression","enrollment":217},{"nctId":"NCT00742573","phase":"PHASE2","title":"Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-08","conditions":"Major Depressive Disorder","enrollment":170},{"nctId":"NCT00590863","phase":"PHASE4","title":"Combining Medications to Enhance Depression Outcomes","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2008-03","conditions":"Major Depressive Disorder","enrollment":665},{"nctId":"NCT00612807","phase":"PHASE1, PHASE2","title":"Treatment of Mood and Marriage Study (TOMMS)","status":"COMPLETED","sponsor":"Duke University","startDate":"2006-07","conditions":"Major Depressive Disorder, Partner Relational Disorder (V61.10)","enrollment":42},{"nctId":"NCT00351910","phase":"PHASE3","title":"Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Major Depressive Disorder","enrollment":494}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["escitalopram","bupropion-SR","escitalopram = Lexapro","bupropion = Wellbutrin","Lexapro"],"phase":"marketed","status":"active","brandName":"Escitalopram + Bupropion SR","genericName":"Escitalopram + Bupropion SR","companyName":"National Institute of Mental Health (NIMH)","companyId":"national-institute-of-mental-health-nimh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination increases serotonin and norepinephrine signaling in the brain through selective serotonin reuptake inhibition and dopamine/norepinephrine reuptake inhibition. Used for Major depressive disorder, Treatment-resistant depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}